Skip to main content

Cost-Effectiveness of Perirectal Surveillance Cultures for Controlling Vancomycin-Resistant Enterococcus

  • Carlene A. Muto (a1), Eve T. Giannetta (a1), Lisa J. Durbin (a1), Barbara M. Simonton (a1) and Barry M. Farr (a1)...

Several hospitals opting not to use active surveillance cultures to identify carriers of vancomycin-resistant Enterococcus (VRE) have reported that adoption of other parts of the Centers for Disease Control and Prevention guideline for controlling VRE has had little to no impact. Because use of surveillance cultures and contact isolation controlled a large outbreak at this hospital, their costs were estimated for comparison with the excess costs of VRE bacteremias occurring at a higher rate at a hospital not employing these measures.


Two university hospitals.


Inpatients deemed high risk for VRE acquisition at this hospital underwent weekly perirectal surveillance cultures. Estimated costs of cultures and resulting isolation during a 2-year period were compared with the estimated excess costs of more frequent VRE bacteremias at another hospital of similar size and complexity not using surveillance cultures to control spread throughout the hospital.


Of 54,052 patients admitted, 10,400 had perirectal swabs taken. Cultures and isolation cost an estimated $253,099. VRE culture positivity was limited to 193 (0.38%) and VRE bacteremia to 1 (0.002%) as compared with 29 bacteremias at the comparison hospital. The estimated attributable cost of VRE bacteremia at the comparison hospital of $761,320 exceeded the cost of the control program at this hospital by threefold.


The excess costs of VRE bacteremia may justify the costs of preventive measures. The costs of VRE infections at other body sites, of deaths from untreatable infections, and of dissemination of genes for vancomycin resistance also help to justify the costs of implementing an effective control program.

Corresponding author
Box 473, University of Virginia Health System, Charlottesville, VA 22908
Hide All
1.Garner JS. Guideline for isolation precautions in hospitals: the Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996;17:5380.
2.Anonymous. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1995;44(RR-12):113.
3.Slaughter S, Hayden MK, Nathan C, et al. A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit. Ann Intern Med 1996;125:448456.
4.Quale J, Landman D, Atwood E, et al. Experience with a hospital outbreak of vancomycin-resistant enterococci. Am J Infect Control 1996;24:372379.
5.Morris JG, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin: establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250259.
6.Byers KE, Anglim AM, Anneski CJ, et al. A hospital epidemic of vancomycin-resistant Enterococcus: risk factors and control. Infect Control Hosp Epidemiol 2001;22:140147.
7.Centers for Disease Control and Prevention. National Nosocomial Surveillance (NNIS) System report, data summary for January 1990-May 1999, issued 1999. Am J Infect Control 2001;29:404421.
8.Wenzel RP, Osterman CA, Hunting KJ, Gwaltney JM Jr. Hospital-acquired infections: I. Surveillance in a university hospital. Am J Epidemiol 1976;103:251260.
9.Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128140.
10.Jernigan JA, Clemence MA, Stott GA, et al. Control of methicillin-resistant Staphylococcus aureus at a university hospital: one decade later. Infect Control Hosp Epidemiol 1995;16:686696.
11.Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998;158:522527.
12.Song X, Perl TM. Vancomycin-resistant enterococcal (VRE) nosocomial bloodstream infections (BSI): the attributable mortality, length of stay, and excess cost. Presented at the 37th Annual Meeting of the Infectious Diseases Society of America; November 18-21, 1999; Philadelphia, PA. Abstract.
13.Rosner B. Fundamentals of Biostatistics. Boston: Duxbury Thomsom Learning; 1990:171177.
14.Jernigan JA, Hadziyannis SC. Vancomycin-resistant Enterococcus faecium (VRE) bacteremia (B) in severely neutropenic patients. Presented at the 36th General Meeting of ICAAC; September 15-18, 1996; New Orleans, LA. Abstract J8:219.
15.Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:9931000.
16.Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin: United States, 1989-1993. MMWR 1993;42:597599.
17.Edmond MB, Jones RN, Pfaller MA, Wallace SE, Wenzel RP. Multicenter surveillance for nosocomial enterococcal bacteremia: a comparison of vancomycin-sensitive vs vancomycin-resistant cases. Infect Control Hosp Epidemiol 1996;17(suppl):18.
18.Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22:663670.
19.Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999;20:318323.
20.Stroud L, Edwards J, Danzing L, Culver D, Gaynes R. Risk factors for mortality associated with enterococcal bloodstream infections. Infect Control Hosp Epidemiol 1996;17:576580.
21.Newell KA, Millis JM, Arnow PM, et al. Incidence and outcome of infection by vancomycin-resistant enterococcus following orthotopic liver transplantation. Transplantation 1998;65:439442.
22.Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998;26:11271133.
23.Bhavnani SM, Drake JA, Forrest Aet al. A nationwide, multicenter, case-control study comparing risk factors, treatment and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000;36:145158.
24.Grumbach K, Osmond D, Vranizan K, Jaffe D, Bindmand AB. Primary care physicians' experience of financial incentives in managed-care systems. N Engl J Med 1998;339:15161521.
25.Simon SR, Pan RJ, Sullivan AM, et al. Views of managed care: a survey of students, residents, faculty, and deans at schools of medical schools in the United States. N Engl J Med 1999;340:928936.
26.Bodenheimer T. The Oregon Health Plan: lessons for the nation. N Engl J Med 1997;337:651655.
27.Cunningham PJ, Grossman JM, St.Peter RF, Lesser CS. Managed care and physicians' provision of charity care. JAMA 1999;281:10871092.
28.Baker LC. Association of managed care market share and health expenditures for fee-for-service Medicare patients. JAMA 1999;281:432437.
29.Bindman AB, Grumbach K, Vranzian K, Jaffe D, Osmond D. Selection and exclusion of primary care physicians by managed care organizations. JAMA 1998;279:675679.
30.Centers for Disease Control and Prevention. Vancomycin-resistant enterococci (VRE) facts: 1999. Available at
31.Anonymous. Public health focus: surveillance, prevention, and control of nosocomial infections. MMWR 1992;41:783787.
32.Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994;271:15981601.
33.Haley RW, Schaberg DR, Crossley KB, Von Allmen SD, McGowan JE Jr. Extra charges and prolongation of stay attributable to nosocomial infections: a prospective inter-hospital comparison. Am J Med 1981;70:5158.
34.Montecalvo MA, Jarvis WR, Uman J, et al. Costs and savings associated with infection control measures that reduce transmission of vancomycin-resistant enterococci in an endemic setting. Infect Control Hosp Epidemiol 2001;22:437442.
35.Hacek DM, Suriano T, Noskin GA, Kruszynski J, Reisberg B, Peterson LR. Medical and economic benefit of a comprehensive infection control program that includes routine determination of microbial clonality. Am J Clin Pathol 1999;111:647654.
36.Boyce JM, Mermel LA, Zervos MJ, et al. Controlling vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 1995;16:634637.
37.Muto CA, Karchmer TB, Cage EG, Durbin LJ, Simonton BM, Farr BM. The utility of culturing roommates of patients with vancomycin-resistant enterococcus. Presented at the 8th Annual Meeting of the Society for Healthcare Epidemiology of America; April 5-7, 1998; Orlando, FL. Abstract 76:38.
38.Calfee DP, Giannetta E, Durbin LJ, Farr BM. Control of vancomycin-resistant Enterococcus colonization among inpatients at a tertiary care facility. Presented at the CDC Fourth Decennial International Conference in Conjunction with the 10th Annual Meeting of the Society for Healthcare Epidemiology of America; March 5-9, 2000; Atlanta, GA. Abstract 69:217.
39.Dembry L, Uzokwe K, Zervos M. Control of endemic glycopeptide-resistant enterococci. Infect Control Hosp Epidemiol 1996;17:286292.
40.Jochimsen EM, Fish L, Manning K, et al. Control of vancomycin-resistant enterococci at a community hospital: efficacy of patient and staff cohorting. Infect Control Hosp Epidemiol 1999;20:106109.
41.Karanfil LV, Murphy M, Josephson A, et al. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992;13:195200.
42.Malik RK, Montecalvo MA, Reale MR, et al. Epidemiology and control of vancomycin-resistant enterococci in a regional neonatal intensive care unit. Pediatr Infect Dis J 1999;18:352356.
43.Rubin LG, Tucci V, Cercenado E, Elipoulos G, Isenberg HD. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect Control Hosp Epidemiol 1992;12:700705.
44.Rupp ME, Marion N, Fey PD, et al. Outbreak of vancomycin-resistant Enterococcus faecium in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2001;22:301303.
45.Ostrowsky BE, Trick WE, Sohn AH, et al. Control of vancomycin-resistant enterococcus in healthcare facilities in a region. N Engl J Med 2001;344:14271433.
46.Siddiqui AH, Harris AD, Hebden J, Wilson PD, Morris JG, Roghmann M. The effect of active surveillance for vancomycin-resistant enterococci in high-risk units on vancomycin-resistant enterococci incidence hospital-wide. Am J Infect Control 2002;30:4043.
47.Reisner BS, Shaw S, Huber ME, et al. Comparison of broth enrichment and direct inoculation of solid media for recovery of vancomycin-resistant enterococci from perirectal and environmental surface samples. Infect Control Hosp Epidemiol 2000;21:775779.
48.Muto CA, Posey K, Pokrywka M, et al. The value of identifying the vancomycin-resistant enterococci (VRE) reservoir using weekly VRE surveillance culturing (VRESC): “The iceberg melts”. Presented at the 12th Annual Meeting of the Society for Healthcare Epidemiology of America; April 6-9, 2002; Salt Lake City, UT.
49.Weinstein JW, Tallapragada S, Farrel P, Dembry LM. Comparison of rectal and perirectal swabs for detection of colonization with vancomycin-resistant enterococci. J Clin Microbiol 1996;34:210212.
50.Rafferty ME, McCormick MI, Bopp LH, et al. Vancomycin-resistant enterococci in stool specimens submitted for Clostridium difficile cytotoxin assay. Infect Control Hosp Epidemiol 1997;18:342344.
51.Leber AL, Hindler JF, Kato EO, Bruckner DA, Pegues DA. Laboratory-based surveillance for vancomycin-resistant enterococci: utility of screening stool specimens submitted for Clostridium difficile toxin assay. Infect Control Hosp Epidemiol 2001;22:160164.
52.Hacek DM, Bednarz P, Noskin GA, Zembower T, Peterson LR. Yield of vancomycin-resistant enterococci and multidrug-resistant Entero-bacteriaceae from stools submitted for Clostridium difficile testing compared to results from a focused surveillance program. J Clin Microbiol 2001;39:11521154.
53.Bradley SJ, Wilson AL, Allen MC, Sher HA, Goldstone AH, Scott GM. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999;43:261266.
54.Quale J, Landman D, Saurina G, Atwood E, DoTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;23:10201025.
55.Salgado C, Sherertz R, Karchmer T, et al. Public health initiative to control MRSA and VRE in Virginia and North Carolina. Presented at the 12th Annual Meeting of the Society for Healthcare Epidemiology of America; April 6-9, 2002; Salt Lake City, UT. Abstract 164:75.
56.Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000;343:19351932.
57.Jones EN, Marshall SA, Pfaller MA, et al. Nosocomial enterococcal bloodstream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group. Diagn Microbiol Infect Dis 1997;29:95102.
58.Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72:195198.
59.Anonymous. Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR 2002;51:565567.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Infection Control & Hospital Epidemiology
  • ISSN: 0899-823X
  • EISSN: 1559-6834
  • URL: /core/journals/infection-control-and-hospital-epidemiology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Full text views

Total number of HTML views: 0
Total number of PDF views: 6 *
Loading metrics...

Abstract views

Total abstract views: 138 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 21st November 2017. This data will be updated every 24 hours.